Muscular Dystrophy, Duchenne Clinical Trial
This study will help to determine the safety and efficacy of the mast cell stabilizer Oxatomide as a treatment for Duchenne muscular dystrophy (DMD). Boys with DMD who are enrolled in this study will should not have taken steroids to treat DMD for at least twelve months, and should not have taken any nutritional supplements for at least three months. Subjects will complete a two screening visits within a one-week period, and if enrolled will then have their strength tested monthly for three months before beginning therapy with Oxatomide. Once Oxatomide therapy is started, participants will have their strength tested monthly for six months. Following the six month treatment period, participants will be given the option to remain on Oxatomide until the study is completed.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01865084 -
A Study of Tadalafil for Duchenne Muscular Dystrophy
|
Phase 3 | |
Completed |
NCT00243789 -
Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT00033189 -
An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT03703882 -
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
|
Phase 3 | |
Enrolling by invitation |
NCT04626674 -
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 1 | |
Completed |
NCT02286947 -
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT03406780 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT01826487 -
Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
|
Phase 3 | |
Completed |
NCT02710591 -
Rimeporide in Patients With Duchenne Muscular Dystrophy
|
Phase 1 | |
Completed |
NCT01826422 -
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients
|
N/A | |
Completed |
NCT00102453 -
Pentoxifylline in Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Terminated |
NCT02090959 -
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
|
Phase 3 | |
Recruiting |
NCT05833633 -
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations
|
||
Completed |
NCT05209087 -
Effects of Parental Influence on Physical Activity Level and Participation in Children With Duchenne Muscular Dystrophy
|
||
Completed |
NCT03789734 -
Safety Study of BLS-M22 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05126758 -
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 3 | |
Completed |
NCT00016653 -
Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Completed |
NCT03127241 -
User-centred Assistive System for Arm Functions in Neuromuscular Subjects
|
N/A | |
Completed |
NCT03490214 -
Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography
|
N/A | |
Completed |
NCT03179631 -
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
|
Phase 3 |